Cloudbreak Pharma Company Profile

Background

Cloudbreak Pharma, established in September 2015 in Irvine, California, is a clinical-stage biotechnology company dedicated to developing innovative ophthalmic drugs. The company's mission is to enhance vision health globally by addressing chronic eye diseases with limited treatment options. Cloudbreak Pharma's team comprises experts with extensive experience in ocular drug research and development, focusing on creating treatments that improve patients' quality of life.

Key Strategic Focus

Cloudbreak Pharma specializes in developing treatments for various ocular conditions, including:

• Pterygium

• Meibomian Gland Dysfunction (MGD)

• Pinguecula

• Glaucoma Filtration Surgery

• Wet Age-Related Macular Degeneration (AMD)

• Myopia Progression

The company's strategic objectives include advancing a broad pipeline of ophthalmic drugs through various stages of clinical development, leveraging proprietary technologies to address unmet medical needs in eye care.

Financials and Funding

Cloudbreak Pharma has secured multiple funding rounds to support its research and development initiatives:

• Series A (October 2018): Raised an undisclosed amount to initiate early-stage development.

• Series B (April 2020): Secured additional funding to advance clinical trials.

• Series C (January 2022): Obtained further investment to expand its pipeline and operations.

In December 2023, Cloudbreak Pharma announced plans for an Initial Public Offering (IPO) to raise capital for ongoing and future projects.

Pipeline Development

Cloudbreak Pharma's pipeline includes several promising candidates:

• CBT-001: A topical eye drop treatment targeting pterygium, currently in multi-regional Phase 3 clinical trials.

• CBT-004: A potential first-in-class drug for vascularized pinguecula, which completed its first patient-in for Phase 2 clinical trials in December 2023 in the U.S.

• CBT-009: A novel ophthalmic formulation of atropine for juvenile myopia, with plans to enter Phase 3 clinical trials in the U.S.

These developments underscore the company's commitment to addressing unmet needs in ophthalmology.

Technological Platform and Innovation

Cloudbreak Pharma distinguishes itself through proprietary technologies and innovative methodologies:

• Multi-Kinase Inhibitor Formulation: Development of potent multi-kinase inhibitors formulated as topical eye drops to treat anterior segment ophthalmic diseases.

• Antibody-Drug Synergism Platform: A unique platform designed to treat posterior segment ophthalmic diseases by combining antibodies with drug compounds for enhanced efficacy.

These platforms enable the company to develop targeted therapies with improved delivery mechanisms and therapeutic outcomes.

Leadership Team

Cloudbreak Pharma's leadership comprises seasoned professionals with diverse expertise:

• Jinsong Ni, Ph.D. – Founder and Chief Executive Officer

• Rebecca Chan, CPA, MBA, LLB – Director and Chief Financial Officer

• Abu Abraham, M.D. – Chief Medical Officer

• Van Dinh, MBA – Chief Operating Officer

• Rong Yang, Ph.D. – Chief Scientific Officer

• Greg Brooks, B.Sc. – Chief Commercial Officer

• W. Ken Fang, Ph.D. – Chief Innovation Officer

• Elizabeth Capan, J.D. – Chief Patent Officer

This team brings extensive experience in ophthalmic drug development, financial management, and strategic operations.

Leadership Changes

In 2022, Cloudbreak Pharma appointed Dr. Abu Abraham as Chief Medical Officer. Dr. Abraham brings over 20 years of experience in pharmaceuticals and medicine, having previously served as Vice President and Global Head of Retina and Vitreous Therapeutics at Santen Pharmaceutical.

Competitor Profile

Market Insights and Dynamics

The ophthalmic drug market is experiencing significant growth, driven by increasing prevalence of eye diseases and advancements in treatment options. The global market is projected to continue expanding, offering substantial opportunities for companies like Cloudbreak Pharma.

Competitor Analysis

Key competitors in the ophthalmic drug development sector include:

• Kala Pharmaceuticals: Focuses on innovative therapies for eye diseases, with products like EYSUVIS for dry eye disease.

• Visus Therapeutics: Develops treatments for presbyopia and other eye conditions, leveraging novel mechanisms of action.

• ONL Therapeutics: Specializes in neuroprotection therapies for retinal diseases, aiming to preserve vision by preventing cell death.

These companies, along with others, contribute to a competitive landscape that drives innovation and development in ophthalmic treatments.

Strategic Collaborations and Partnerships

Cloudbreak Pharma has established significant partnerships to enhance its market position and innovation capacity:

• Santen Pharmaceutical Co., Ltd.: In August 2024, Cloudbreak entered into a licensing agreement with Santen for CBT-001, granting Santen rights to develop, manufacture, and commercialize the drug in Japan, South Korea, Vietnam, Thailand.